Turn Therapeutics (TTRX) Cash from Financing Activities (2024 - 2026)

Turn Therapeutics' Cash from Financing Activities history runs 3 years deep, the most recent figure standing at $7.8 million for Q1 2026.

• In Q1 2026, Cash from Financing Activities rose 680.14% year-over-year to $7.8 million; the TTM figure through Mar 2026 stood at $12.5 million (changed N/A YoY), while the FY2025 annual figure was $6.9 million, up 500.45% from the prior year.
• Cash from Financing Activities for Q1 2026 stood at $7.8 million, up from $3.2 million in the prior quarter.
• The five-year high for Cash from Financing Activities was $7.8 million in Q1 2026, with the low at $522206.0 in Q4 2024.
• The 3-year median for Cash from Financing Activities is $2.1 million (2025), against an average of $3.1 million.
• The sharpest annual moves came in 2025 and 2026: Cash from Financing Activities soared 508.51% in 2025, then jumped 680.14% in 2026.
• Turn Therapeutics' Cash from Financing Activities stood at $522206.0 in 2024, then jumped by 508.51% to $3.2 million in 2025, then jumped by 145.04% to $7.8 million in 2026.
• Business Quant data shows TTRX's Cash from Financing Activities at $7.8 million in Q1 2026, $3.2 million in Q4 2025, and $998092.0 in Q1 2025.